-
Mashup Score: 46Highlights of ASH 2024: Focus on Multiple Myeloma - 3 day(s) ago
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m…
Source: opmed.doximity.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 46Highlights of ASH 2024: Focus on Multiple Myeloma - 3 day(s) ago
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m…
Source: opmed.doximity.comCategories: General Medicine News, Hem/OncsTweet-
Highlights of ASH 2024: Focus on Multiple Myeloma #bmtsm #mmsm #ASH24 https://t.co/2eoZptGt68 via @doximity
-
-
Mashup Score: 46Highlights of ASH 2024: Focus on Multiple Myeloma - 3 day(s) ago
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m…
Source: opmed.doximity.comCategories: General Medicine News, Hem/OncsTweet-
Highlights of ASH 2024: Focus on Multiple Myeloma #bmtsm #mmsm #ASH24 https://t.co/2eoZptGt68 via @doximity
-
-
Mashup Score: 3
Blood Cancer Journal – Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
@Rfonsi1 @mvmateos @Vero_Glez_Calle I agree. We published a paper earlier this year, and on MVA only 1q amp (4 or more copies) was associated with a shorter PFS https://t.co/iKmnPWUnuX
-
-
Mashup Score: 19
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
GMMG-HD7 trial: Isa-VRD vs. VRD in transplant-eligible NDMM, N=662, Significantly higher MRD -ve (66 vs. 48%) and longer PF (3-year PFS: 88 vs. 71%) with Isa-VRD #bmtsm #mmsm @EliasKarlMai @JCO_ASCO https://t.co/3G0Dtrz2kb https://t.co/aNjStzubWN
-
-
Mashup Score: 72
This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four diffe…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. N=1304, Gain 1q seen in 43% patients, all others in <10%. t(4;14), del 17p (>20% cells) and Gain 1q => shorter PFS and OS #bmtsm #mmsm @mvmateos @Vero_Glez_Calle https://t.co/S0URb6ZP2y
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Measurable Residual Disease Smith Giri, MD, MHS 1 *, Binod Dhakal, MBBS 2, Natalie Callander, MD 3, Eva Medvedova, MD 4 *, Kelly Godby 1 *, Susan Bal, MD 1, Gayathri Ravi, MD 1, Saurabh Chhabra, MD 5,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 In the setting of quadruplet induction + autoSCT in NDMM, sustained MRD at 10e-5 is the best predictor of MRD resurgence and progression after fixed duration Rx #bmtsm #mms @smith__giri @End_myeloma https://t.co/BqWf3cv7Wl
-
-
Mashup Score: 17Paper: Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma - 22 day(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and P lasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes Hematology Disease Topics & Pathways: Research, Adult, Translational Research, Plasma Cell Disorders, Bioinformatics, Diseases, Lymphoid Malignancies, Computational biology, Technology and Procedures, Study Population, Human, Measurable Residual Disease Palak Bajaj 1 *, Ola Landgren 2, Damian J. Green, MD 3 and David G.
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma. Validation in larger prospective studies needed @DrOlaLandgren #mmsm https://t.co/dLcH3w7xhn
-
-
Mashup Score: 0The best books of 2024, as chosen by The Economist - 23 day(s) ago
Readers will never think the same way again about games, horses and spies
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet-
The best books of 2024, as chosen by The Economist https://t.co/PBrJ6WBMJc
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 Dara-Len vs. Len maintenance in NDMM, MRD+ post ASCT (AURIGA trial). N=200, higher MRD (10^-5 NGS) and PFS with Dara-Len. Higher gr 3/4 TEAE with Dara-Len #mmsm #bmtsm @ldandersonjr https://t.co/jfvL4Pi0Dj
-
Highlights of ASH 2024: Focus on Multiple Myeloma #bmtsm #mmsm #ASH24 https://t.co/2eoZptGt68 via @doximity